Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice

Parasite Immunology

Volumn 35, Issue 12, 2013, Pages 397-408

  Saljoughian, N ^a   Zahedifard, F ^a   Doroud, D ^a   Doustdari, F ^a   Vasei, M ^b   Papadopoulou, B ^c,d   Rafati, S ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cationic solid lipid nanoparticles; Delivery systems; DNA vaccination; Electroporation; Mice model; Visceral leishmaniasis

Indexed keywords

DNA LEISHMANIA DONOVANI A2 ANTIGEN CYSTEINE PROTEINASE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; NITRIC OXIDE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; ELECTROPORATION; FEMALE; HISTOPATHOLOGY; HUMORAL IMMUNITY; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROVOCATION TEST; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

CATIONIC SOLID-LIPID NANOPARTICLES; DELIVERY SYSTEMS; DNA VACCINATION; ELECTROPORATION; MICE MODEL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYSTEINE PROTEASES; ELECTROPORATION; FEMALE; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LIPIDS; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARASITE LOAD; PROTOZOAN PROTEINS; VACCINATION; VACCINES, DNA;

EID: 84887168748     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12042     Document Type: Article

References (54)

1. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 1996; 55: 125-130.
2. Desjeux P & Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97: 3-15.
3. Alvar J, Aparicio P, Aseffa A, et al. The relationship between Leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: 334-359.
4. Croft S, Vivas L & Brooker S. Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis. East Mediterr Health J 2003; 9: 518-533.
5. Choi C & Lerner E. Leishmaniasis as an emerging infection. J Investig Dermatol Symp Proc 2001; 6: 175-182.
6. Carvalho JA, Rodgers J, Atouguia J, Prazeres DM & Monteiro GA. DNA vaccines: a rational design against parasitic diseases. Expert Rev Vaccines 2010; 9: 175-191.
7. Charest H & Matlashewski G. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol 1994; 14: 2975-2984.
8. Zhang WW & Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001; 39: 935-948.
9. Ghosh A, Zhang WW & Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001; 20: 59-66.
10. Mizbani A, Taheri T, Zahedifard F, et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 2009; 28: 53-62.
11. Rafati S, Nakhaee A, Taheri T, et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005; 23: 3716-3725.
12. Rafati S, Zahedifard F & Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006; 24: 2169-2175.
13. Rafati S, Salmanian AH, Taheri T, Vafa M & Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 2001; 19: 3369-3375.
14. Somiari S, Glasspool-Malone J, Drabick JJ, et al. Theory and in vivo application of electroporative gene delivery. Mol Ther 2000; 2: 178-187.
15. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177: 437-447.
16. Taghian DG & Nickoloff JA. Electrotransformation of Chinese hamster ovary cells. Methods Mol Biol 1995; 48: 115-121.
17. Drabick JJ, Glasspool-Malone J, King A & Malone RW. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 2001; 3: 249-255.
18. Liu F & Huang L. A Syringe Electrode Device for Simultaneous Injection of DNA and Electrotransfer. Mol Ther 2002; 5: 323-328.
19. Withers HR, Peters LJ & Taylor JM. Dose-response relationship for radiation therapy of subclinical disease. Int J Radiat Oncol Biol Phys 1995; 31: 353-359.
20. Weaver JC. Electroporation theory. Concepts and mechanisms. Methods Mol Biol 1995; 47: 1-26.
21. Hartikka J, Sukhu L, Buchner C, et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4: 407-415.
22. Doroud D, Vatanara A, Zahedifard F, et al. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J Pharm Pharm Sci 2010; 13: 320-335.
23. Doroud D, Zahedifard F, Vatanara A, et al. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl Trop Dis 2011; 5: e1236.
24. Doroud D, Zahedifard F, Vatanara A, et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 2011; 153: 154-162.
25. Viana da Costa A, Huerre M, Delacre M, Auriault C, Correia Costa JM & Verwaerde C. IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. Parasitol Int 2002; 51: 367-379.
26. Buffet PA, Sulahian A, Garin YJ, Nassar N & Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 1995; 39: 2167-2168.
27. Kharazmi A, Kemp K, Ismail A, et al. T-cell response in human leishmaniasis. Immunol Lett 1999; 65: 105-108.
28. Alexander J & McFarlane E. Can type-1 responses against intracellular pathogens be T helper 2 cytokine dependent? Microbes Infect 2008; 10: 953-959.
29. Silvestre R, Cordeiro-Da-Silva A, Santarem N, Vergnes B, Sereno D & Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J Immunol 2007; 179: 3161-3170.
30. Carrion J, Nieto A, Iborra S, et al. Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol 2006; 28: 173-183.
31. Gurunathan S, Klinman DM & Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 2000; 18: 927-974.
32. Kutzler MA & Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9: 776-788.
33. Ulmer JB, Wahren B & Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006; 12: 216-222.
34. Wallace M, Evans B, Woods S, et al. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther 2009; 17: 922-928.
35. Mehnert W & Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-196.
36. Olbrich C, Bakowsky U, Lehr CM, Muller RH & Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 2001; 77: 345-355.
37. Muller RH, Mader K & Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
38. Muller RH, Dingler A, Schneppe T & Gohla S. Large scale production of solid lipid nanoparticles (SLNe) and nanosuspensions. In: Wise D (ed.): Handbook of Pharmaceutical Controlled Release Technology. New York, NY, USA, Marcel Dekker, 2000: 359-376 (DissoCubesw).
39. Schwarz C & Mehnert W. Sterilization of drug-free and tetracaineloaded solid lipid nanoparticles (SLN). Proceedings of the First World Meeting APGI/APV. 1995; Budapest:485-486.
40. Asasutjarit R, Lorenzen SI, Sirivichayakul S, Ruxrungtham K, Ruktanonchai U & Ritthidej GC. Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection. Pharm Res 2007; 24: 1098-1107.
41. Look M, Bandyopadhyay A, Blum JS & Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev 2010; 62: 378-393.
42. Alexander J & Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 2005; 99: 17-23.
43. Sisto M, Brandonisio O, Panaro MA, et al. Inducible nitric oxide synthase expression in Leishmania-infected dog macrophages. Comp Immunol Microbiol Infect Dis 2001; 24: 247-254.
44. Brandonisio O, Panaro MA, Sisto M, et al. Nitric oxide production by Leishmania-infected macrophages and modulation by cytokines and prostaglandins. Parassitologia 2001; 43(Suppl. 1): 1-6.
45. Haldar JP, Ghose S, Saha KC & Ghose AC. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 1983; 42: 702-707.
46. Wilson ME, Jeronimo SM & Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 2005; 38: 147-160.
47. Kaye PM, Curry AJ & Blackwell JM. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 1991; 146: 2763-2770.
48. Melby PC, Chandrasekar B, Zhao W & Coe JE. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent th1- like cytokine response. J Immunol 2001; 166: 1912-1920.
49. Nieto A, Domínguez-Bernal G, Orden JA, Fuente RDL, Madrid-Elena N & Carrión J. Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model. Vet Res 2011; 42: 39.
50. Rolao N, Cortes S, Gomes-Pereira S & Campino L. Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice. Exp Parasitol 2007; 115: 270-276.
51. Murray HW, Squires KE, Miralles CD, et al. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol 1992; 148: 1858-1863.
52. Stager S, Alexander J, Carter KC, Brombacher F & Kaye PM. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 2003; 71: 4804-4807.
53. Stanley AC & Engwerda CR. Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 2007; 85: 138-147.
54. Engwerda CR, Ato M & Kaye PM. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol 2004; 20: 524-530.